Aquestive Therapeutics

Yahoo Finance • 13 days ago

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST)... Full story

Yahoo Finance • 14 days ago

AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in A... Full story

Yahoo Finance • 29 days ago

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

Lake Street lowered the firm’s price target on Aquestive Therapeutics (AQST) to $6 from $8 and keeps a Buy rating on the shares after the company announced the receipt of a CRL for Anaphylm and a planned resubmission in Q3. The firm adjust... Full story

Yahoo Finance • 29 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyto... Full story

Yahoo Finance • 30 days ago

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

Leerink analyst Roanna Ruiz was not surprised that Aquestive Therapeutics (AQST) received a Complete Response Letter for Anaphylm given the FDA’s prior deficiency letter. That said, the “silver lining” is that this outcome appears recovera... Full story

Yahoo Finance • 4 months ago

Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec”

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is one of the stocks Jim Cramer recently put under a microscope. When a caller asked about the stock, Cramer stated: “We know the problem. Let’s not look at that. We look at the pipeline and we k... Full story

Yahoo Finance • 4 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ... Full story

Yahoo Finance • 5 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylax... Full story

Yahoo Finance • 5 months ago

Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID

(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close mov... Full story

Yahoo Finance • 6 months ago

Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Aquestive Therapeutics (NASDAQ:AQST [https://seekingalpha.com/symbol/AQST]) added ~15% in the premarket on Thursday after announcing t... Full story

Yahoo Finance • 6 months ago

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquest... Full story

Yahoo Finance • 7 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ... Full story

Yahoo Finance • 7 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential commercialization of Anaphylm... Full story

Yahoo Finance • 7 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany... Full story

Yahoo Finance • 7 months ago

Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday

Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he... Full story

Yahoo Finance • 8 months ago

Aquestive schedules regulatory meetings for epinephrine film in Canada, EU

WARREN, N.J. - Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with a market capitalization of $400 million and showing strong momentum with a 9.5% return last week, announced today that Health Canada has granted the c... Full story

Yahoo Finance • 8 months ago

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, In... Full story

Yahoo Finance • 8 months ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative... Full story

Yahoo Finance • 8 months ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ... Full story